The US Food and Drug Administration’s risk-based approach to postmarketing drug safety monitoring entails weekly screening of individual adverse event reports for three years after approval of certain drugs and biologics, the agency explains in a new draft document.
Products receiving weekly screening during their first three years on the market include: new molecular entities, novel biologics, biosimilars, and...




